WO2022075313A1 - 標的物質の検出方法、流体デバイス及びキット - Google Patents
標的物質の検出方法、流体デバイス及びキット Download PDFInfo
- Publication number
- WO2022075313A1 WO2022075313A1 PCT/JP2021/036802 JP2021036802W WO2022075313A1 WO 2022075313 A1 WO2022075313 A1 WO 2022075313A1 JP 2021036802 W JP2021036802 W JP 2021036802W WO 2022075313 A1 WO2022075313 A1 WO 2022075313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- well
- target substance
- volume
- array
- substance
- Prior art date
Links
- 239000013076 target substance Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 49
- 239000012530 fluid Substances 0.000 title claims description 39
- 239000000126 substance Substances 0.000 claims abstract description 51
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 239000003960 organic solvent Substances 0.000 claims abstract description 26
- 238000007789 sealing Methods 0.000 claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 230000005284 excitation Effects 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims description 59
- 239000002250 absorbent Substances 0.000 claims description 21
- 239000008393 encapsulating agent Substances 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 7
- 238000006297 dehydration reaction Methods 0.000 claims description 7
- 230000001678 irradiating effect Effects 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 19
- 150000007523 nucleic acids Chemical class 0.000 description 68
- 235000018102 proteins Nutrition 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 60
- 238000003556 assay Methods 0.000 description 23
- 239000000523 sample Substances 0.000 description 21
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 20
- 108020005004 Guide RNA Proteins 0.000 description 20
- 108091033409 CRISPR Proteins 0.000 description 17
- 238000010354 CRISPR gene editing Methods 0.000 description 17
- 108091079001 CRISPR RNA Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000000565 sealant Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108700004991 Cas12a Proteins 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 238000010791 quenching Methods 0.000 description 11
- 230000000171 quenching effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- -1 saliva Substances 0.000 description 7
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 4
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 4
- 241000605861 Prevotella Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 108091069025 single-strand RNA Proteins 0.000 description 3
- FLTJDUOFAQWHDF-UHFFFAOYSA-N 2,2-dimethylhexane Chemical compound CCCCC(C)(C)C FLTJDUOFAQWHDF-UHFFFAOYSA-N 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N 2-Methylheptane Chemical compound CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- LAIUFBWHERIJIH-UHFFFAOYSA-N 3-Methylheptane Chemical compound CCCCC(C)CC LAIUFBWHERIJIH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N Heptadecane Natural products CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010025538 Malignant ascites Diseases 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000611831 Prevotella sp. Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012946 outsourcing Methods 0.000 description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JXPOLSKBTUYKJB-UHFFFAOYSA-N xi-2,3-Dimethylhexane Chemical compound CCCC(C)C(C)C JXPOLSKBTUYKJB-UHFFFAOYSA-N 0.000 description 2
- WGECXQBGLLYSFP-UHFFFAOYSA-N (+-)-2,3-dimethyl-pentane Natural products CCC(C)C(C)C WGECXQBGLLYSFP-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- OKVWYBALHQFVFP-UHFFFAOYSA-N 2,3,3-trimethylpentane Chemical compound CCC(C)(C)C(C)C OKVWYBALHQFVFP-UHFFFAOYSA-N 0.000 description 1
- LVLXQRZPKUFJJQ-UHFFFAOYSA-N 2,3-dimethylhex-1-ene Chemical compound CCCC(C)C(C)=C LVLXQRZPKUFJJQ-UHFFFAOYSA-N 0.000 description 1
- RCBGGJURENJHKV-UHFFFAOYSA-N 2-methylhept-1-ene Chemical compound CCCCCC(C)=C RCBGGJURENJHKV-UHFFFAOYSA-N 0.000 description 1
- XTVRLCUJHGUXCP-UHFFFAOYSA-N 3-methyleneheptane Chemical compound CCCCC(=C)CC XTVRLCUJHGUXCP-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BWDBEAQIHAEVLV-UHFFFAOYSA-N 6-methylheptan-1-ol Chemical compound CC(C)CCCCCO BWDBEAQIHAEVLV-UHFFFAOYSA-N 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241001135194 Capnocytophaga canimorsus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101000860098 Lachnospiraceae bacterium (strain NK4A179) CRISPR-associated endoribonuclease Cas13a Proteins 0.000 description 1
- 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 1
- 241000412895 Lachnospiraceae bacterium NK4A179 Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000162745 Porphyromonas gulae Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241001116196 Prevotella saccharolytica Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000001312 dry etching Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- XLMFDCKSFJWJTP-UHFFFAOYSA-N pentane-2,3-diol Chemical compound CCC(O)C(C)O XLMFDCKSFJWJTP-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6452—Individual samples arranged in a regular 2D-array, e.g. multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N2021/6482—Sample cells, cuvettes
Definitions
- the present invention relates to a method for detecting a target substance, a fluid device and a kit.
- the present application claims priority based on Japanese Patent Application No. 2020-169092 filed in Japan on October 6, 2020, the contents of which are incorporated herein by reference.
- ABSx Activity-Based Diagnostics
- Diseases to be diagnosed by ABDx include infectious diseases such as virus infection, non-communicable diseases such as cancer, and the like.
- virus infection can be detected by detecting a nucleic acid derived from a virus as a marker.
- cancer can be detected by detecting the activity of an enzyme such as cathepsin that has become uncontrollable in cancer tissue as a marker of disease.
- cfDNA cell-free DNA
- ctDNA blood tumor DNA
- exosomes secrete membrane vesicles
- biological samples such as saliva, blood, urine, amniotic fluid, and malignant ascites, and in the supernatant of cultured cells.
- Exosomes contain various proteins, lipids, microRNAs, DNAs, etc. derived from the cells that secrete them.
- microRNA DNA
- DNA DNA
- membrane vesicles such as cfDNA and exosomes
- Patent Document 1 describes that enzyme activity is detected at the single molecule level using a microchamber having a size on the order of femtolitre.
- an object of the present invention is to provide a technique capable of detecting a target substance with high sensitivity.
- the present invention includes the following aspects.
- a method for detecting a target substance in a sample wherein the sample and a reagent that produces a fluorescent substance when the target substance is present are introduced into each well of the well array, and the well.
- the step of producing the fluorescent substance when the target substance is present in the contents while being dehydrated and the volume is reduced, and the fluorescence generated by irradiating the fluorescent substance with excitation light is generated in the well array.
- a method comprising a step of detecting for each well, wherein the detection of fluorescence in the well indicates the presence of the target substance in the well.
- Each well of the well array has a first well and a second well which is arranged at the bottom of the first well and has a smaller volume than the first well. The method according to [1], wherein when the volume of the contents of the first well becomes smaller, the contents are accumulated in the second well.
- the ratio of the volume of the first well to the volume of the second well is 10: 1 to 1,000,000: 1. 2] The method described in.
- [4] The method according to [2] or [3], wherein the volume of the first well is 1 to 1,000 pL and the volume of the second well is 0.1 to 1,000 fL.
- [5] The method according to any one of [2] to [4], wherein 0 or 1 of the target substance is introduced into each of the first wells.
- FIG. 1 A and (b) are schematic diagrams illustrating an example of a method for detecting a target substance.
- A is a schematic diagram illustrating an example of a well array having a first well and a second well.
- (B) is a cross-sectional view taken along the line b-b'of (a).
- A) is a schematic diagram illustrating an example of a well array having a first well and a second well.
- (B) is a cross-sectional view taken along the line b-b'of (a).
- (A)-(f) are schematic cross-sectional views explaining each process of manufacturing a well array.
- A) and (b) are schematic cross-sectional views explaining each process of manufacturing a well array.
- (A) is a top view showing an example of a fluid device.
- (B) is a cross-sectional view taken along the line b-b'of (a).
- (A) to (d) are schematic cross-sectional views illustrating an example of a procedure for carrying out a method for detecting a target substance using a fluid device. It is a micrograph of a well array.
- (A) to (d) are photographs showing the results of Experimental Example 1.
- (A) and (b) are graphs showing the results of Experimental Example 1. It is a graph which shows the result of Experimental Example 1. It is a graph which shows the result of Experimental Example 2. It is a graph which shows the result of Experimental Example 3.
- the present invention is a method for detecting a target substance in a sample, in which the sample and a reagent that produces a fluorescent substance when the target substance is present are introduced into each well of the well array.
- the contents of the well are dehydrated to reduce the volume, and the fluorescent substance is generated when the target substance is present in the contents, and the fluorescent substance is irradiated with excitation light to generate the fluorescent substance.
- a step of detecting fluorescence for each well of the well array is provided, and the detection of fluorescence in the wells provides a method for indicating the presence of the target substance in the wells.
- the target substance can be detected with high sensitivity.
- sample The sample is not particularly limited, and examples thereof include biological samples such as saliva, blood, urine, amniotic fluid, malignant ascites, pharyngeal swab, and nasal swab, and supernatants of cultured cells.
- the target substance is not particularly limited, and examples thereof include an enzyme, a single-stranded nucleic acid fragment, a double-stranded nucleic acid fragment, and the like.
- the nucleic acid fragment may be a nucleic acid derived from a virus, cfDNA, ctDNA, miRNA, or the like.
- the enzyme any enzyme can be targeted, and examples thereof include a main protease of coronavirus, alkaline phosphatase, and a protease derived from a living body. Examples of the protease derived from a living body include serine protease, cysteine protease, cathepsin and the like.
- reagent that produces a fluorescent substance in the presence of a target substance examples include a fluorescent substrate corresponding to the target enzyme when the target substance is an enzyme.
- a fluorescent substrate is one in which a fluorescent substance is produced by an enzymatic reaction.
- a peptide substrate labeled with a fluorescent substance and a quenching substance can be mentioned. Fluorescence is detected when such peptide substrates are cleaved by peptidases.
- the enzyme is phosphatase, a fluorescent substance or the like that is quenched by adding a phosphate group can be mentioned. Fluorescence is detected when the phosphate group is removed from such a substance.
- Cas12 and Cas13 form a tripartite complex with gRNA and target nucleic acid, and when the target nucleic acid is cleaved, the surrounding DNA or RNA is cleaved. It has been clarified that it expresses the activity of
- a fluorescent substance can be produced by using a single-stranded nucleic acid fragment or a double-stranded nucleic acid fragment as a target substance (target nucleic acid).
- a target substance target nucleic acid
- a double-stranded DNA fragment can be detected as a target substance.
- a single-stranded RNA fragment or a single-stranded DNA fragment can be detected as a target substance.
- FIGS. 1 (a) and 1 (b) are schematic views illustrating this reaction.
- the case where the CRISPR / Cas family protein is the Cas12a protein will be described as an example.
- Cas12a protein 110 and gRNA 120 are brought into contact with each other, they bind to each other to form a two-way complex 130.
- the gRNA 120 partially has a base sequence complementary to the target nucleic acid fragment 140 (target substance).
- the Cas12a protein 110 does not express nuclease activity, so the substrate nucleic acid fragment 150 is not cleaved.
- the substrate nucleic acid fragment 150 is a single-stranded DNA fragment labeled with the fluorescent substance F and the quenching substance Q. No fluorescence is generated even when the substrate nucleic acid fragment 150 is irradiated with excitation light.
- FIG. 1A is a schematic diagram showing a tripartite complex 100'in which the target site of the target nucleic acid fragment 140 has been cleaved.
- FIG. 1 (b) the tripartite complex 100'expresses nuclease activity.
- the substrate nucleic acid fragment 150 existing around the tripartite complex 100' is cleaved.
- the fluorescent substance F of the substrate nucleic acid fragment 150 is separated from the quenching substance Q. Fluorescence can be detected by irradiating the fluorescent substance F away from the quenching substance Q with excitation light. When fluorescence is detected, it can be determined that the target nucleic acid fragment 140 was present in the sample.
- the reagents for which the fluorescent substance is generated in the presence of the target substance are CRISPR / Cas family protein 110, gRNA 120 and substrate nucleic acid fragment 150.
- the sample, CRISPR / Cas family protein 110, gRNA 120, and substrate nucleic acid fragment 150 may be mixed and contacted in any order.
- the CRISPR / Cas family protein 110 and the gRNA 120 may be first contacted to form the two-party complex 130 in advance, and then the sample may be contacted.
- the target nucleic acid fragment 140 when the target nucleic acid fragment 140 is present in the sample, the target nucleic acid fragment 140 binds to the two-way complex 130 to form the three-way complex 100.
- the substrate nucleic acid fragment 150 may then be contacted.
- the target nucleic acid fragment 140 and the substrate nucleic acid fragment 150 may be brought into contact at the same time.
- the CRISPR / Cas family protein 110, gRNA120, and sample may be brought into contact at the same time. Even in this case, if the target nucleic acid fragment 140 is present in the sample, the tripartite complex 100 is finally formed. The substrate nucleic acid fragment 150 may then be contacted.
- the sample, CRISPR / Cas family protein 110, gRNA 120, and substrate nucleic acid fragment 150 may be brought into contact at the same time. Even in this case, if the target nucleic acid fragment 140 is present in the sample, the tripartite complex 100 is finally formed, and when the target site of the target nucleic acid fragment 140 is cleaved in the tripartite complex 100, It is converted to a tripartite complex 100', expresses nuclease activity, and cleaves the substrate nucleic acid fragment 150.
- the guide RNA is not particularly limited as long as it can be used for the CRISPR / Cas family protein to be used, and is limited to CRISPR RNA (crRNA) and trans-activated CRISPR RNA (tracrRNA). It may be a complex with, a single gRNA (sgRNA) which is a combination of tracrRNA and crRNA, or may be only crRNA.
- the crRNA can be, for example, the following base sequence.
- the base sequence obtained by removing the protospacer adjacent motif (PAM) sequence from the target base sequence is used as the spacer base sequence.
- PAM protospacer adjacent motif
- a base sequence in which a scaffold sequence is linked is designed at the 3'end of the spacer base sequence, and the complementary strand thereof is used as the base sequence of crRNA.
- the base sequence obtained by removing the PAM sequence from the target base sequence is "5'-GCCAAGCGCACCTAATTTCC-3'" (SEQ ID NO: 1)
- the base sequence of crRNA for Cas12a protein is "5'-AAUUUCUACUAAGUGUAGAUGGAAAUUAGGUGCGCUUGGC-3'”. (SEQ ID NO: 2) can be used.
- the crRNA can be, for example, the following base sequence.
- a base sequence in which a scaffold sequence is linked is designed at the 3'end of a base sequence complementary to the target base sequence, and the complementary strand is used as the base sequence of crRNA.
- the target base sequence is "5'-AUGGAUUACUUGGUAGAACAGCAAUCUA-3'" (SEQ ID NO: 3)
- the base sequence of crRNA for Cas13a protein is "5'-GAUUUAGACUACCCCAAAAACGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU-3'" (SEQ ID NO: 4). Can be done.
- CRISPR / Cas family protein any protein that expresses nuclease activity after forming a tripartite complex with gRNA and a target nucleic acid fragment can be used. As mentioned above, more precisely, it forms a tripartite complex and expresses nuclease activity after the CRISPR / Cas family protein cleaves the target nucleic acid fragment.
- CRISPR / Cas family proteins examples include Cas12 protein and Cas13 protein.
- the Cas12 protein and Cas13 protein may be Cas12 protein, Cas13 protein, orthologs of these proteins, variants of these proteins, and the like.
- CRISPR / Cas family proteins that can be used in the method of the present embodiment, for example, Lachnospiraceae bacterium ND2006-derived Cas12a protein (LbCas12a, UniProtKB accession number: A0A182DWE3), Acidaminococcus. Derived Cas12a protein (AsCas12a, UniProtKB accession number: U2UMQ6), Francisella tularensis subsp.
- Cas12a protein (FnCas12a, UniProtKB accession number: A0Q7Q2) derived from novicida
- Cas12b protein (AaCas12b, UniProtKB accession number: T0D7A2) derived from Ali Prevotellarestris (AaCas12b, UniProtKB accession number: T0D7A2), Le ),
- Cas13a protein derived from Lachnospiraceae bacterium NK4A179 (LbaCas13a, NCBI accession number: WP_022785443.1), Leptotricia baccaris C-1013-b derived Cas13a protein (LbaCya Cas13b protein (BzoCas13b, NCBI accession number: WP_002664492), Prevotella intermediaia-derived Cas13b protein (PinCas13b, NCBI accession number: WP_036860899), Prevo
- MA2016-derived Cas13b protein (PsmCas13b, NCBI accession number: WP_036929175), Reemerella anatipestifer-derived Cas13b protein (RanCas13b, NCBI accession number: WP_004919755), Prevotellasession number: WP_004919755, Prevotella Prevotella saccharolytica derived Cas13b protein (PsaCas13b, NCBI accession number: WP_051522484), Cas13b protein derived from Prevotella intermedia (Pin2Cas13b, NCBI accession number: WP_061868553), Cas13b protein derived from Capnocytophaga canimorsus (CcaCas13b, NCBI accession number: WP_013997271) , Porphyromonas gulae-derived Cas13b protein (PguCas13b, NCBI accession number: WP_039434803)
- Cas13b protein derived from P5-125 (PspCas13b, NCBI accession number: WP_044065294), Cas13b protein derived from Porphyromonas gingivalis (PigCas13b, NCBI accession number: WP_0534444117), Prevotella ), Csm6 protein derived from Enteroccus italicus (EiCsm6, NCBI accession number: WP_007208953.1), Csm6 protein derived from Lactobacillus salivalius (LsCsm6, NCBI accession number: WP_081509) Accession number: WP_11229148.1) and the like can be mentioned.
- the CRISPR / Cas family protein may be a variant of the Cas family protein described above.
- the mutant for example, a mutant having increased nuclease activity after forming a tripartite complex can be used.
- Substrate nucleic acid fragment is labeled with a fluorescent substance and a quenching substance, and when the fluorescent substance is cleaved by the nuclease activity of the tripartite complex and the fluorescent substance separates from the quenching substance, it emits fluorescence by irradiation with excitation light. ..
- the substrate nucleic acid fragment may be appropriately selected according to the substrate specificity of the CRISPR / Cas family protein to be used.
- the Cas12 protein is cleaved using single-stranded DNA as a substrate. Therefore, when Cas12 protein is used, single-stranded DNA may be used as the substrate nucleic acid fragment.
- Cas13 protein is cleaved using single-strand RNA as a substrate. Therefore, when Cas13 protein is used, it is preferable to use single-strand RNA as a substrate nucleic acid fragment.
- the combination of the fluorescent substance and the quenching substance a combination that can quench the fluorescence of the fluorescent substance when they are brought close to each other is used.
- a combination that can quench the fluorescence of the fluorescent substance when they are brought close to each other is used.
- FAM, HEX, or the like is used as the fluorescent substance
- Iowa Black FQ (IDT), TAMRA, or the like can be used as the quenching substance.
- each well of the well array has a first well and a second well located at the bottom of the first well and having a smaller volume than the first well. As the volume of the contents of the first well becomes smaller, the contents may be accumulated in the second well.
- FIG. 2 (a) and 2 (b) are schematic views illustrating an example of a well array having a first well and a second well.
- 2 (a) is a top view
- FIG. 2 (b) is a cross-sectional view taken along the line b-b'of FIG. 2 (a).
- the well array 200 is formed on one surface of the substrate 210.
- Each well of the well array 200 has a first well 220 and a second well 230 located at the bottom of the well 220 and having a smaller capacity than the well 220. As will be described later, when the volume of the contents of the first well 220 becomes smaller, the contents are accumulated in the second well 230.
- the target substance can be detected with high sensitivity, and the time required for detection is shortened.
- the volume ratio of the first well 220 to the second well 230 may be 10: 1 to 1,000,000: 1.
- the volume of the first well 220 may be 1 to 1,000 pL, and the volume of the second well 230 may be 0.1 to 1,000 fL.
- FIG. 3 (a) and 3 (b) are schematic views illustrating another example of a well array having a first well and a second well.
- 3 (a) is a top view
- FIG. 3 (b) is a cross-sectional view taken along the line b-b'of FIG. 3 (a).
- the well array 300 is formed on one surface of the substrate 210.
- a plurality of second wells 230 may be arranged per first well 220. Also in this case, when the volume of the contents of the first well 220 becomes smaller, the contents are accumulated in the second well 230.
- the shapes of the first well 220 and the second well 230 are not particularly limited, and may be, for example, a cylinder, a polyhedron composed of a plurality of faces (for example, a rectangular parallelepiped, a hexagonal column, an octagonal column, etc.). good.
- the plurality of first wells 220 have the same shape and size
- the plurality of second wells 230 have the same shape and size.
- the same shape and the same size may be used as long as they have the same shape and the same capacity to the extent required for digital measurement, and variations of the degree of manufacturing error are allowed.
- FIGS. 5 (a) and 5 (b) are schematic cross-sectional views illustrating each step of manufacturing the well array 300.
- the film 400 is laminated on the surface of the substrate 210.
- Examples of the material of the substrate 210 include glass, resin, and the like.
- Examples of the resin include polyethylene, polypropylene, polystyrene, polycarbonate, cyclic polyolefin, acrylic and the like.
- Examples of the material of the film 400 include fluororesin, cyclic polyolefin, and silicone resin.
- the resist film 410 is laminated on the surface of the film 400. Subsequently, the resist film 410 is exposed by irradiating the resist film 410 with active energy rays using the mask of the well array pattern. Subsequently, it is developed with a developing solution, and as shown in FIG. 4D, the resist film 410 at the portion forming the well is removed.
- the film 400 masked with the resist film 410 is etched to form the second well 230 in the film 400.
- the resist film 410 is removed by cleaning the substrate to obtain an array of wells 230.
- the resist film 410 is laminated again on the array of wells 230 obtained in FIG. 4F.
- a sheet-type resist can be preferably used as the resist film 410.
- the resist film 410 is exposed by irradiating the resist film 410 with active energy rays using a mask with a well array pattern. Subsequently, it is developed with a developing solution to remove the resist film 410 at the portion forming the first well 220. As a result, a well array 300 having a first well 220 and a second well 230 is obtained.
- the method of the present embodiment it is preferable to introduce 0 or 1 target substance per 1st well.
- Digital measurement can be performed by introducing 0 or 1 target substance per 1st well. That is, the number of wells in which fluorescence is detected can be made to correspond to the number of molecules of the target substance in the sample.
- the encapsulant is preferably immiscible with water.
- Immiscible with water means that water and the encapsulant are sufficiently mixed and then allowed to stand to separate into an aqueous phase and an organic phase.
- the sealing liquid preferably has low water absorption. Low water absorption means that the volume change of the organic layer is 1% or less when it is mixed with water of equal volume and allowed to stand at 20 ° C. and separated into an aqueous phase and an organic phase.
- the sealing liquid a substance having a boiling point of about 100 ° C. or higher and liquid at room temperature can be used.
- Specific encapsulants include fluorine such as FC-40, FC-43, FC-770, FC-72, FC-3283 (all manufactured by 3M), and von Bryn (registered trademark) oil (Solvay). Examples thereof include system liquids, mineral oils (Sigmar Aldrich Co., Ltd.), straight-chain or branched-chain saturated or unsaturated hydrocarbons having 7 to 17 carbon atoms. These may be used alone or in combination of two or more.
- Linear or branched saturated or unsaturated hydrocarbons having 7 to 17 carbon atoms include heptane (C 7 H 16 ), octene (C 8 H 18 ), nonan (C 9 H 20 ), and dodecane (C 9 H 20).
- examples of the isomer of octane include 1-octane, 2-methylheptane, 3-methylheptane, 2,2-dimethylhexane, 2,3-dimethylhexane, 2,3,3-trimethylpentane and the like.
- examples of the isomers of octene include 1-octene, 2-methyl-1-heptene, 2,3-dimethyl-1-hexene, 2-ethyl-1-hexene, and 2,3,3-trimethyl-1. -Butene etc. can be mentioned.
- Water-absorbent organic solvent As the water-absorbent organic solvent, a water-absorbent organic solvent having a boiling point of about 100 ° C. or higher, liquid at room temperature, and immiscible with water can be used, and is linear or branched with 4 to 11 carbon atoms. Examples include chain saturated or unsaturated aliphatic alcohols. Immiscible with water means that water and an organic solvent are sufficiently mixed and then allowed to stand to separate into an aqueous phase and an organic phase. Further, water absorption means that water is dissolved.
- the water-absorbent organic solvent may be a monohydric alcohol or a divalent or higher alcohol.
- Specific water-absorbing organic solvents include butanol (C 4 H 10 O), pentanol (C 5 H 12 O), hexanol (C 6 H 14 O), heptanol (C 7 H 16 O), and octanol. (C 8 H 18 O), nonanol (C 9 H 20 O), decanol (C 10 H 22 O), undecanol (C 11 H 24 O), pentanediol (C 5 H 12 O 2 ) and the like can be mentioned. These may be any isomer. In addition, these may be used alone or in combination of two or more.
- examples of the isomer of octanol include 1-octanol, isooctyl alcohol, 2-ethylhexanol and the like.
- examples of the isomer of pentanediol include 1,5-pentanediol, 1,2-pentanediol, 2,3-pentanediol and the like.
- the invention comprises a well array comprising a first well and a plurality of wells located at the bottom of the first well and having a second well having a smaller volume than the first well.
- the well array and the lid member have a substrate arranged on the surface thereof, a lid member arranged so as to face the well array, and a spacer for separating the substrate and the lid member from each other. The space between them provides a fluid device, forming a flow path through which the fluid flows.
- the substrate on which the well array is arranged on the surface is the same as that described above.
- FIG. 6A is a top view showing an example of the fluid device of the present embodiment.
- FIG. 6 (b) is a cross-sectional view taken along the line b-b'of FIG. 6 (a).
- the fluid device 600 is located at the bottom of the first well 220 and the first well 220, and has a smaller capacity than the first well 220. It has a substrate 210 on which a well array 200 having a plurality of wells having wells 230 is arranged on the surface, a spacer 610, and a lid member 620 forming a liquid inlet 621.
- the space 630 between the substrate 210 and the lid member 620 functions as a flow path for flowing a sample, a detection reagent, a sealing liquid, a water-absorbent organic solvent, and the like.
- the fluid device of this embodiment can be suitably used for the above-mentioned application of the target substance detection method.
- the method for detecting the target substance includes a step of introducing the sample and a reagent that produces a fluorescent substance when the target substance is present into each well of the well array, and each of the well arrays.
- the fluorescent substance is generated when the target substance is present in the contents, and the fluorescent substance is irradiated with excitation light, and the generated fluorescence is generated for each well of the well array.
- FIGS. 7 (a) to 7 (d) are schematic cross-sectional views illustrating an example of a procedure for carrying out a method for detecting a target substance.
- a single-strand RNA fragment tgRNA
- crRNA gRNA
- substrate nucleic acid fragment are used as reagents for producing a fluorescent substance in the presence of a target substance.
- an assay solution 710 in which a sample, Cas13a protein, crRNA, and a substrate nucleic acid fragment are mixed is introduced from the liquid inlet 621 of the fluid device 600.
- the interior of the well 220, the interior of the well 230, and the space 630 between the substrate 210 and the lid member 620 are filled with the assay solution 710. That is, a sample and a reagent that produces a fluorescent substance when a target substance is present are introduced into each well of the well array.
- each well of the well array is sealed with a sealing liquid.
- the sealant 720 is introduced from the liquid introduction port 621.
- the opening of the well 220 is sealed with the sealant 720 with the assay solution 710 filled inside the well 220.
- each well forms an independent reaction space.
- the encapsulant 720 is replaced with a water-absorbent organic solvent 730.
- the contents of the well assay solution 710) are dehydrated, the volume is reduced (concentrated), and the three-way complex of Cas13a-crRNA-tgRNA in the assay solution 710 forms a substrate nucleic acid fragment (Reporter). Disconnect.
- the fluorescent substance F bound to the substrate nucleic acid fragment is separated from the quenching substance Q and becomes fluorescent when irradiated with the excitation light. Fluorescence detected in a well indicates the presence of a target substance in that well.
- the substrate nucleic acid fragment is not cleaved and fluorescence does not occur because the ternary complex of Cas13a-crRNA-tgRNA is not formed.
- the water-absorbent organic solvent 730 may be replaced with the sealing agent 720 again. This allows the dehydration of the well contents (assay solution 710) to be stopped. That is, the method for detecting the target substance in the sample may further include a step of replacing the water-absorbent organic solvent with the encapsulant.
- the target substance is captured in the large-capacity well 220 to improve the capture probability of the target substance, and the detection is performed in the small-capacity well 230 to detect the target substance with high sensitivity. And the time required for detection is shortened.
- the present invention comprises a target substance detection kit comprising the fluid device described above, a reagent that produces a fluorescent substance in the presence of the target substance, a sealant, and a water-absorbing organic solvent. I will provide a.
- the above-mentioned method for detecting a target substance can be suitably carried out.
- the fluid device is the same as that described above. Further, the same applies to the target substance, the reagent for which the fluorescent substance is generated when the target substance is present, the encapsulant, and the water-absorbent organic solvent.
- the target nucleic acid fragment (single-stranded RNA fragment, SEQ ID NO: 5) was chemically synthesized by outsourcing (IDT).
- gRNA DNA fragment encoding gRNA (crRNA) was prepared by PCR amplification using an overlapping primer containing a T7 promoter sequence, a 20-base target sequence and a scaffold sequence as a template. Subsequently, the obtained DNA fragment was subjected to an in vitro transcription reaction to prepare crRNA.
- the base sequence of gRNA (crRNA) for Cas13a protein is shown in SEQ ID NO: 4.
- Substrate nucleic acid fragments (single-stranded RNA fragments) were chemically synthesized by outsourcing (IDT).
- the 5'end of the substrate nucleic acid fragment was labeled with FAM, a fluorescent material, and the 3'end was labeled with Iowa Black FQ (IDT), a quencher.
- the base sequence of the chemically synthesized substrate nucleic acid fragment (single-stranded RNA fragment) was "5'-(FAM) UUUUU (IABkFQ) -3'" (where "IABkFQ" indicates Iowa Black FQ). ..
- the well array A was produced by the same procedure as in FIGS. 4 (a) to 4 (f) described above. First, as shown in FIG. 4A, the glass substrate 210 was immersed in an 8M potassium hydroxide solution for about 24 hours to form a hydroxyl group on the surface.
- a fluororesin (CYTOP, manufactured by AGC Co., Ltd.) was spin-coated on the surface of the glass substrate 210 to form a film 400.
- the spin coating conditions were set to 1,000 rpm (revolutions per minute) for 30 seconds. Under this condition, the film thickness of the film 400 is about 1.8 ⁇ m.
- the film 400 was brought into close contact with the surface of the glass substrate 210 by dehydrating and condensing the silanol group of the film 400 (CYTOP) and the hydroxyl group on the glass surface by baking on a hot plate at 180 ° C. for 1 hour.
- CYTOP silanol group of the film 400
- a resist product name "AZ-P4903", manufactured by AZ Electrical Materials
- AZ-P4903 manufactured by AZ Electrical Materials
- the glass substrate 210 was baked on a hot plate at 110 ° C. for 1 hour to evaporate the organic solvent in the resist film 410, whereby the resist film 410 was brought into close contact with the surface of the film 400.
- the resist film 410 was exposed by irradiating the resist film 410 with ultraviolet rays at 250 W for 14 seconds with an exposure machine (manufactured by Union Optical Co., Ltd.) using a mask with a well array pattern. Subsequently, it was immersed in a developing solution (AZ developer, manufactured by AZ Electrical Materials) for 1.5 minutes for development. As a result, the resist film 410 at the portion forming the well was removed.
- AZ developer manufactured by AZ Electrical Materials
- the film 400 masked with the resist film 410 is subjected to 30 under the conditions of O 2 200 sccm, pressure 5 Pa, and output 50 W using a Reactive ion etching apparatus (manufactured by YAC). Wells 230 were formed on the film 400 by dry etching for a minute.
- the resist film 410 was removed by immersing the glass substrate 210 in acetone, washing with isopropanol, and then washing with pure water to remove the resist film 410, and the array of wells 230 (well array A).
- the well array A had a shape in which 1,500,000 columnar wells 230 having a diameter of 3.5 ⁇ m and a depth of 1.8 ⁇ m were arranged in 1 cm 2 .
- Well 230 The volume per well was 17 fL.
- a well array B having a first well and a second well was prepared by the same procedure as in FIGS. 4 (a) to 4 (f), FIGS. 5 (a) and 5 (b).
- the well array obtained in the same manner as in FIGS. 4 (a) to 4 (f) is dry-etched (O 2 13 sccm, pressure 14 Pa, output 125 W) for 5 seconds using a reactive ion etching apparatus (manufactured by Samco). Therefore, the surface of the well array was hydrolyzed.
- a sheet-type resist product name "SU-8 3020CF DFR Type-S", KAYAKU Advanced Materials, Inc.
- a laminating roller As shown in FIG. 5A, a resist film 410 was formed.
- the resist film 410 was exposed by irradiating ultraviolet rays for 20 seconds with an exposure machine (manufactured by Union Optical Co., Ltd.) using a mask with a well array pattern. Subsequently, it was immersed in a developing solution (product name "SU8 developer", KAYAKU Advanced Materials, Inc.) for 8 minutes for development. As a result, the resist film 410 at the portion forming the well was removed, and a well array B having the first well 220 and the second well 230 was obtained.
- a developing solution product name "SU8 developer", KAYAKU Advanced Materials, Inc.
- the well array B consists of a well array in which 1,500,000 columnar wells 230 having a diameter of 3.5 ⁇ m and a depth of 1.8 ⁇ m are arranged in 1 cm 2 and a columnar well 220 having a diameter of 40 ⁇ m and a depth of 20 ⁇ m. It had a shape in which 40,000 well arrays were stacked in 1 cm 2 .
- the well array B had a shape in which 12 to 18 wells 230 were arranged at the bottom of each well 220.
- FIG. 8 is a photomicrograph of the prepared well array B.
- an assay solution in which the above-mentioned tripartite complex solution and a solution of the substrate nucleic acid fragment were mixed was prepared, and immediately introduced from the liquid inlet of each fluid device A. As a result, the assay solution was introduced into each well of the well array.
- FIG. 9 (a) is a representative fluorescence micrograph showing the result of the assay solution in which the final concentration of the target nucleic acid fragment is 0 pM.
- FIG. 9B is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 0.3 pM.
- FIG. 9 (c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 3 pM.
- FIG. 9 (d) is a representative fluorescence micrograph showing the result of the assay solution in which the final concentration of the target nucleic acid fragment is 30 pM.
- the scale bar is 50 ⁇ m.
- FIG. 10A is a typical graph showing the number of wells showing a predetermined fluorescence intensity (relative value) based on a photograph of a well array into which each assay solution was introduced.
- FIG. 10 (b) shows the same graph as in FIG. 10 (a) for assay solutions in which the final concentrations of the target nucleic acid fragments are 30 pM, 3 pM, 0.3 pM, and 0 pM, respectively, in FIG. 10 (a). It is a graph which enlarged and arranged the area corresponding to the area surrounded by a dotted line.
- FIG. 11 is a graph showing the relationship between the number of wells in which fluorescence was detected and the final concentration of the target nucleic acid fragment.
- the vertical axis shows the number of wells in which fluorescence was detected, and the horizontal axis shows the final concentration of the target nucleic acid fragment.
- a sealant (hexadecane, Sigma-Aldrich) was introduced from the liquid inlet of the fluid device B.
- a sealant hexadecane, Sigma-Aldrich
- a water-absorbent organic solvent was introduced from the liquid inlet of the fluid device B to replace the encapsulant.
- the water-absorbent organic solvent 1-pentanol, 1-hexanol, 1-heptanol, 1-octanol, and 1-nonanol were examined.
- the contents of the well were dehydrated, the volume was reduced, and the alkaline phosphatase in the contents reacted with sTG-phos to produce a fluorescent substance (sTG).
- sTG fluorescent substance
- the chemical formula of sTG is shown in the following formula (2).
- FIG. 12 is a graph showing the results of measuring the change over time in the fluorescence intensity (relative value) of sTG when each water-absorbent organic solvent is used.
- a sealant (hexadecane, Sigma-Aldrich) was introduced from the liquid inlet of the fluid device B.
- a sealant hexadecane, Sigma-Aldrich
- 1-octanol was introduced from the liquid inlet of the fluid device to replace the encapsulant.
- the contents of the well were dehydrated, the volume was reduced, and the alkaline phosphatase in the contents reacted with sTG-phos to produce a fluorescent substance (sTG).
- FIG. 13 is a representative graph showing the percentage of wells showing a predetermined fluorescence intensity (relative value) based on a photograph of a well array in which fluorescence of sTG was detected.
- the horizontal axis of the graph shows the concentration of alkaline phosphatase (ALP).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
[1]試料中の標的物質の検出方法であって、ウェルアレイの各ウェルに、前記試料、及び、前記標的物質が存在する場合に蛍光物質が生成される試薬を導入する工程と、前記ウェルアレイの各ウェルを封止液で封止し、各ウェルがそれぞれ独立した反応空間を形成する工程と、前記封止液を吸水性の有機溶媒に置換し、その結果、前記ウェルの内容物が脱水され、容積が減少すると共に、前記内容物中に前記標的物質が存在する場合に前記蛍光物質が生成される工程と、前記蛍光物質に励起光を照射し、発生する蛍光を前記ウェルアレイのウェルごとに検出する工程と、を含み、前記ウェルで蛍光が検出されたことが、前記ウェルに前記標的物質が存在することを示す、方法。
[2]前記ウェルアレイの各ウェルが、第1のウェルと、前記第1のウェルの底部に配置され、前記第1のウェルよりも小容量の第2のウェルとを有しており、前記第1のウェルの内容物の容積が小さくなると、前記内容物が前記第2のウェルに集積する、[1]に記載の方法。
[3]前記第1のウェルと前記第2のウェルの容積の比(第1のウェルの容積:第2のウェルの容積)が、10:1~1,000,000:1である、[2]に記載の方法。
[4]前記第1のウェルの容積が1~1,000pLであり、前記第2のウェルの容積が0.1~1,000fLである、[2]又は[3]に記載の方法。
[5]前記標的物質が、前記第1のウェル1つあたりに0個又は1個導入される、[2]~[4]のいずれかに記載の方法。
[6]前記封止液が、フッ素系液体、ミネラルオイル又は炭素数7~17の直鎖状又は分岐鎖状の飽和若しくは不飽和の炭化水素である、[1]~[5]のいずれかに記載の方法。
[7]前記吸水性の有機溶媒が、炭素数4~11の直鎖状又は分岐鎖状の飽和若しくは不飽和の脂肪族アルコールである、[1]~[6]のいずれか一項に記載の方法。
[8]第1のウェルと、前記第1のウェルの底部に配置され、前記第1のウェルよりも小容量の第2のウェルとを有するウェルを複数備えたウェルアレイが表面に配置された基板と、前記ウェルアレイに対向して配置された蓋部材と、前記基板及び前記蓋部材との間を離間させるスペーサーと、を有し、前記ウェルアレイと前記蓋部材との間の空間は流体が流れる流路を形成している、流体デバイス。
[9][8]に記載の流体デバイスと、標的物質が存在する場合に蛍光物質が生成される試薬と、封止液と、吸水性の有機溶媒とを含む、標的物質検出用キット。
1実施形態において、本発明は、試料中の標的物質の検出方法であって、ウェルアレイの各ウェルに、前記試料、及び、前記標的物質が存在する場合に蛍光物質が生成される試薬を導入する工程と、前記ウェルアレイの各ウェルを封止液で封止し、各ウェルがそれぞれ独立した反応空間を形成する工程と、前記封止液を吸水性の有機溶媒に置換し、その結果、前記ウェルの内容物が脱水され、容積が減少すると共に、前記内容物中に前記標的物質が存在する場合に前記蛍光物質が生成される工程と、前記蛍光物質に励起光を照射し、発生する蛍光を前記ウェルアレイのウェルごとに検出する工程と、を含み、前記ウェルで蛍光が検出されたことが、前記ウェルに前記標的物質が存在することを示す方法を提供する。
試料としては、特に限定されず、例えば、唾液、血液、尿、羊水、悪性腹水、咽頭ぬぐい液、鼻腔ぬぐい液等の生体試料や、培養細胞の上清等が挙げられる。
標的物質としては、特に限定されず、酵素、1本鎖核酸断片、2本鎖核酸断片等が挙げられる。核酸断片は、ウイルス由来の核酸、cfDNA、ctDNA、miRNA等であってもよい。酵素としては、あらゆる酵素を対象とすることができ、例えば、コロナウイルスのメインプロテアーゼ、アルカリフォスファターゼ、生体由来のプロテアーゼ等が挙げられる。生体由来のプロテアーゼとしては、例えば、セリンプロテアーゼ、システインプロテアーゼ、カテプシン等が挙げられる。
標的物質が存在する場合に蛍光物質が生成される試薬(検出試薬)としては、標的物質が酵素である場合には、対象とする酵素に対応した蛍光基質が挙げられる。このような蛍光基質は、酵素反応により蛍光物質が生成されるものである。
本実施形態の方法において、ガイドRNA(gRNA)は、使用するCRISPR/Casファミリータンパク質に用いることができるものであれば特に限定されず、CRISPR RNA(crRNA)とトランス活性化型CRISPR RNA(tracrRNA)との複合体であってもよいし、tracrRNAとcrRNAを組み合わせた単一のgRNA(sgRNA)であってもよいし、crRNAのみであってもよい。
CRISPR/Casファミリータンパク質としては、gRNA及び標的核酸断片と3者複合体を形成した後にヌクレアーゼ活性を発現するものであれば用いることができる。上述したように、より正確には、3者複合体を形成し、CRISPR/Casファミリータンパク質が標的核酸断片を切断した後に、ヌクレアーゼ活性を発現する。
基質核酸断片は、蛍光物質及び消光物質で標識されており、前記3者複合体のヌクレアーゼ活性により切断されて前記蛍光物質が前記消光物質から離れると、励起光の照射により蛍光を発するものである。
本実施形態の方法において、ウェルアレイの各ウェルが、第1のウェルと、第1のウェルの底部に配置され、第1のウェルよりも小容量の第2のウェルとを有しており、第1のウェルの内容物の容積が小さくなると、内容物が第2のウェルに集積するものであってもよい。
ウェルアレイ300を例に、第1のウェル及び第2のウェルを有するウェルアレイの製造方法の一例を説明する。
封止液は、水と混和しないものであることが好ましい。水と混和しないとは、水と封止液を十分混合した後、静置すると、水相及び有機相に分離することを意味する。また、封止液は、吸水性が低いことが好ましい。吸水性が低いとは、20℃において等容量の水と混合して静置し、水相及び有機相に分離した場合の有機層の体積変化が1%以下であることを意味する。
吸水性の有機溶媒としては、沸点が約100℃以上であり、室温で液体であり、水と混和しない、吸水性の有機溶媒使用することができ、炭素数4~11の直鎖状又は分岐鎖状の飽和若しくは不飽和の脂肪族アルコールが挙げられる。水と混和しないとは、水と有機溶媒を十分混合した後、静置すると、水相及び有機相に分離することを意味する。また、吸水性とは、水を溶解することを意味する。吸水性の有機溶媒は、一価のアルコールであってもよく、二価以上のアルコールであってもよい。
1実施形態において、本発明は、第1のウェルと、前記第1のウェルの底部に配置され、前記第1のウェルよりも小容量の第2のウェルとを有するウェルを複数備えたウェルアレイが表面に配置された基板と、前記ウェルアレイに対向して配置された蓋部材と、前記基板及び前記蓋部材との間を離間させるスペーサーと、を有し、前記ウェルアレイと前記蓋部材との間の空間は流体が流れる流路を形成している、流体デバイスを提供する。
ここで、図7(a)~(d)を参照しながら、上述した実施形態に係る標的物質の検出方法をより具体的に説明する。
1実施形態において、本発明は、上述した流体デバイスと、標的物質が存在する場合に蛍光物質が生成される試薬と、封止液と、吸水性の有機溶媒とを含む、標的物質検出用キットを提供する。
(Cas13aタンパク質の調製)
Leptotrichia wadei Cas13a(LwCas13a)の発現ベクターを大腸菌BL21(DE3)株にトランスフェクションして発現させた。発現ベクターは、N末端に、10×Hisタグ、マルトース結合タンパク質(MBP)及びTEVプロテアーゼ切断部位を有するpETベースのベクターであった。発現したCas13aタンパク質はNi-NTA樹脂を用いて精製した。続いて、TEVプロテアーゼを4℃、一晩反応させた後、MBPTrap HPカラム(GEヘルスケア社)及びこれに接続したHiTrap Heparin HPカラム(GEヘルスケア社)を用いてカチオン交換クロマトグラフィーを行い、更にSuperdex 200カラム(GEヘルスケア社)を用いたゲルろ過クロマトグラフィーにより精製した。
標的核酸断片(一本鎖RNA断片、配列番号5)は外注(IDT社)により化学合成した。
T7プロモーター配列、20塩基の標的配列及びスキャフォールド配列を含むオーバーラッピングプライマーを鋳型としたPCR増幅により、gRNA(crRNA)をコードするDNA断片を調製した。続いて、得られたDNA断片をインビトロ転写反応に供しcrRNAを調製した。Cas13aタンパク質用のgRNA(crRNA)の塩基配列を配列番号4に示す。
基質核酸断片(一本鎖RNA断片)は外注(IDT社)により化学合成した。基質核酸断片の5’末端を蛍光物質であるFAMで標識し、3’末端を消光物質であるIowa Black FQ(IDT社)で標識した。化学合成した基質核酸断片(一本鎖RNA断片)の塩基配列は「5'-(FAM)UUUUU(IABkFQ)-3'」(ここで、「IABkFQ」はIowa Black FQを示す。)であった。
上述した、図4(a)~(f)と同様の手順により、ウェルアレイAを作製した。まず、図4(a)に示すように、ガラス基板210を8Mの水酸化カリウム溶液に24時間程度浸し、表面にヒドロキシル基を形成させた。
図4(a)~(f)、図5(a)及び(b)と同様の手順により、第1のウェル及び第2のウェルを有するウェルアレイBを作製した。まず、図4(a)~(f)と同様にして得られたウェルアレイを、Reactice ion etching装置(Samco社製)を用いて5秒間ドライエッチング(O2 13sccm、圧力14Pa、出力125W)することで、ウェルアレイ表面の親水化処理を行った。続いて、ウェルアレイを65℃のホットプレート上に置き、ラミネートローラーを用いてシート型レジスト(製品名「SU-8 3020CF DFR Type-S」、KAYAKU Advanced Materials, Inc.社製)を密着させ、図5(a)に示すように、レジスト膜410を形成した。
図6と同様にして、上述したウェルアレイAにスペーサー220を配置し、更に、液体導入口621を形成したガラス板620を載せ、流体デバイスAを作製した。この結果、ウェルアレイAとガラス板620との間の空間が流路である流体デバイスAが得られた。
図6と同様にして、上述したウェルアレイBにスペーサー220を配置し、更に、液体導入口621を形成したガラス板620を載せ、流体デバイスBを作製した。この結果、ウェルアレイBとガラス板620との間の空間が流路である流体デバイスBが得られた。
(Cas13aを用いた検討)
Cas13aタンパク質、gRNA(配列番号4)及び標的核酸断片を、Cas13aタンパク質の終濃度が40nMとなり、gRNAの終濃度が25nMとなり、標的核酸断片の終濃度が、それぞれ、30pM、3pM、0.3pM、0pMとなるように、下記表1に示す組成のバッファーAに混合し、3者複合体を形成させた。以下、この溶液を3者複合体溶液という。
(濃縮の検討1)
150fMのアルカリフォスファターゼ(シグマ-アルドリッチ社)と、1μMの蛍光基質(sTG-phos)を混合したアッセイ溶液を調製し、上述した流体デバイスBの液体導入口から導入した。sTG-phosの化学式を下記式(1)に示す(Sakamoto S., et al., Multiplexed single-molecule enzyme activity analysis for counting disease-related proteins in biological samples, Sci Adv. 6 (11), eaay0888, 2020. を参照。)。この結果、アッセイ溶液がウェルアレイの各ウェルに導入された。
(濃縮の検討2)
段階希釈したアルカリフォスファターゼ(シグマ-アルドリッチ社)と、1μMの蛍光基質(sTG-phos)を混合したアッセイ溶液を調製し、上述した流体デバイスBの液体導入口から導入した。この結果、アッセイ溶液がウェルアレイの各ウェルに導入された。
Claims (9)
- 試料中の標的物質の検出方法であって、
ウェルアレイの各ウェルに、前記試料、及び、前記標的物質が存在する場合に蛍光物質が生成される試薬を導入する工程と、
前記ウェルアレイの各ウェルを封止液で封止し、各ウェルがそれぞれ独立した反応空間を形成する工程と、
前記封止液を吸水性の有機溶媒に置換し、その結果、前記ウェルの内容物が脱水され、容積が減少すると共に、前記内容物中に前記標的物質が存在する場合に前記蛍光物質が生成される工程と、
前記蛍光物質に励起光を照射し、発生する蛍光を前記ウェルアレイのウェルごとに検出する工程と、
を含み、前記ウェルで蛍光が検出されたことが、前記ウェルに前記標的物質が存在することを示す、方法。 - 前記ウェルアレイの各ウェルが、第1のウェルと、前記第1のウェルの底部に配置され、前記第1のウェルよりも小容量の第2のウェルとを有しており、前記第1のウェルの内容物の容積が小さくなると、前記内容物が前記第2のウェルに集積する、請求項1に記載の方法。
- 前記第1のウェルと前記第2のウェルの容積の比(第1のウェルの容積:第2のウェルの容積)が、10:1~1,000,000:1である、請求項2に記載の方法。
- 前記第1のウェルの容積が1~1,000pLであり、前記第2のウェルの容積が0.1~1,000fLである、請求項2又は3に記載の方法。
- 前記標的物質が、前記第1のウェル1つあたりに0個又は1個導入される、請求項2~4のいずれか一項に記載の方法。
- 前記封止液が、フッ素系液体、ミネラルオイル又は炭素数7~17の直鎖状又は分岐鎖状の飽和若しくは不飽和の炭化水素である、請求項1~5のいずれか一項に記載の方法。
- 前記吸水性の有機溶媒が、炭素数4~11の直鎖状又は分岐鎖状の飽和若しくは不飽和の脂肪族アルコールである、請求項1~6のいずれか一項に記載の方法。
- 第1のウェルと、前記第1のウェルの底部に配置され、前記第1のウェルよりも小容量の第2のウェルとを有するウェルを複数備えたウェルアレイが表面に配置された基板と、
前記ウェルアレイに対向して配置された蓋部材と、
前記基板及び前記蓋部材との間を離間させるスペーサーと、を有し、
前記ウェルアレイと前記蓋部材との間の空間は流体が流れる流路を形成している、流体デバイス。 - 請求項8に記載の流体デバイスと、標的物質が存在する場合に蛍光物質が生成される試薬と、封止液と、吸水性の有機溶媒とを含む、標的物質検出用キット。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180080274.4A CN116615526A (zh) | 2020-10-06 | 2021-10-05 | 靶标物质的检测方法、流体装置及试剂盒 |
EP21877612.8A EP4227398A1 (en) | 2020-10-06 | 2021-10-05 | Method for detecting target substance, fluid device, and kit |
JP2022555500A JPWO2022075313A1 (ja) | 2020-10-06 | 2021-10-05 | |
US18/029,567 US20230366820A1 (en) | 2020-10-06 | 2021-10-05 | Method for detecting target substance, fluid device, and kit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-169092 | 2020-10-06 | ||
JP2020169092 | 2020-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022075313A1 true WO2022075313A1 (ja) | 2022-04-14 |
Family
ID=81126922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/036802 WO2022075313A1 (ja) | 2020-10-06 | 2021-10-05 | 標的物質の検出方法、流体デバイス及びキット |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230366820A1 (ja) |
EP (1) | EP4227398A1 (ja) |
JP (1) | JPWO2022075313A1 (ja) |
CN (1) | CN116615526A (ja) |
WO (1) | WO2022075313A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023195542A1 (ja) * | 2022-04-08 | 2023-10-12 | 国立研究開発法人理化学研究所 | 複数種類の標的核酸断片を検出する方法及びキット |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004309405A (ja) | 2003-04-10 | 2004-11-04 | Univ Tokyo | 一分子酵素活性検出に用いられるマイクロチャンバ |
WO2005023124A2 (en) * | 2003-09-10 | 2005-03-17 | Ovature Research Inc. | Apparatus for handling cells, embryos or oocytes |
JP2012529643A (ja) * | 2009-06-09 | 2012-11-22 | オックスフォード・ジーン・テクノロジー・アイピー・リミテッド | 単一細胞または他の粒子の分析用ピコウェル捕捉装置 |
WO2017043530A1 (ja) * | 2015-09-08 | 2017-03-16 | 凸版印刷株式会社 | 生体物質検出方法 |
JP2019066480A (ja) * | 2012-05-25 | 2019-04-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | マイクロ流体デバイス、複数の反応ウェルを含むマイクロ流体デバイスへの試薬の提供方法および反応の遂行方法 |
JP2020169092A (ja) | 2019-04-04 | 2020-10-15 | 花王株式会社 | シート移送方法 |
-
2021
- 2021-10-05 US US18/029,567 patent/US20230366820A1/en active Pending
- 2021-10-05 JP JP2022555500A patent/JPWO2022075313A1/ja active Pending
- 2021-10-05 EP EP21877612.8A patent/EP4227398A1/en active Pending
- 2021-10-05 WO PCT/JP2021/036802 patent/WO2022075313A1/ja active Application Filing
- 2021-10-05 CN CN202180080274.4A patent/CN116615526A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004309405A (ja) | 2003-04-10 | 2004-11-04 | Univ Tokyo | 一分子酵素活性検出に用いられるマイクロチャンバ |
WO2005023124A2 (en) * | 2003-09-10 | 2005-03-17 | Ovature Research Inc. | Apparatus for handling cells, embryos or oocytes |
JP2012529643A (ja) * | 2009-06-09 | 2012-11-22 | オックスフォード・ジーン・テクノロジー・アイピー・リミテッド | 単一細胞または他の粒子の分析用ピコウェル捕捉装置 |
JP2019066480A (ja) * | 2012-05-25 | 2019-04-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | マイクロ流体デバイス、複数の反応ウェルを含むマイクロ流体デバイスへの試薬の提供方法および反応の遂行方法 |
WO2017043530A1 (ja) * | 2015-09-08 | 2017-03-16 | 凸版印刷株式会社 | 生体物質検出方法 |
JP2020169092A (ja) | 2019-04-04 | 2020-10-15 | 花王株式会社 | シート移送方法 |
Non-Patent Citations (4)
Title |
---|
"NCBI", Database accession no. WP_081509150.1 |
"UniProtKB", Database accession no. A0A182DWE3 |
SAKAMOTO S. ET AL.: "Multiplexed single-molecule enzyme activity analysis for counting disease-related proteins in biological samples", SCI ADV., vol. 6, no. 11, 2020 |
SOLEIMANY A.P.BHATIA S.N.: "Activity-Based Diagnostics: An Emerging Paradigm for Disease Detection and Monitoring", TRENDS MOL MED, vol. 26, no. 5, 2020, pages 450 - 468, XP055791005, DOI: 10.1016/j.molmed.2020.01.013 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023195542A1 (ja) * | 2022-04-08 | 2023-10-12 | 国立研究開発法人理化学研究所 | 複数種類の標的核酸断片を検出する方法及びキット |
Also Published As
Publication number | Publication date |
---|---|
US20230366820A1 (en) | 2023-11-16 |
CN116615526A (zh) | 2023-08-18 |
EP4227398A1 (en) | 2023-08-16 |
JPWO2022075313A1 (ja) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021002476A1 (ja) | 標的核酸断片の検出方法及びキット | |
CN102137719B (zh) | 核酸提取装置 | |
US10597692B2 (en) | Mass spectrometric diagnosis of sepsis without blood culture | |
Hass et al. | Integrated micropillar polydimethylsiloxane accurate CRISPR detection system for viral DNA sensing | |
KR101006562B1 (ko) | 핵산 추출 방법 | |
AU2010272586A1 (en) | Mass spectrometric diagnosis of septicemia | |
CN102639716A (zh) | 使用二维cDNA文库的基因表达解析方法 | |
Iino et al. | A single-cell drug efflux assay in bacteria by using a directly accessible femtoliter droplet array | |
WO2022075313A1 (ja) | 標的物質の検出方法、流体デバイス及びキット | |
US20190270979A1 (en) | Nucleic acid extraction method using solid subject | |
CN109996875A (zh) | 使用dtbp浓缩微生物或提取核酸的方法 | |
CN111662804A (zh) | 用于食品微生物检测的数字环介导等温扩增的微流控芯片 | |
Zhu et al. | A novel microfluidic device integrated with chitosan-modified capillaries for rapid ZIKV detection | |
Wang et al. | An Integrated amplification-free digital CRISPR/Cas-assisted assay for single molecule detection of RNA | |
JP3041423B1 (ja) | 集積化されたマイクロウェルを用いたポリメラ―ゼ連鎖反応装置 | |
Chen et al. | Microfluidics: the propellant of CRISPR-based nucleic acid detection | |
Liu et al. | Toward rapid and accurate molecular diagnostics at home | |
Kang et al. | An electrophoretic DNA extraction device using a nanofilter for molecular diagnosis of pathogens | |
EP4269581A1 (en) | Method and kit for detecting target nucleic acid fragment | |
CN112592815B (zh) | 一种进行多重microRNA检测的微流控芯片及应用 | |
JPWO2020067122A1 (ja) | アルカリホスファターゼ組成物並びに脱リン酸化核酸及び標識化核酸の製造方法 | |
US20170369928A1 (en) | Method for evaluating dna damage from analyte | |
WO2023195542A1 (ja) | 複数種類の標的核酸断片を検出する方法及びキット | |
CN102839211A (zh) | 用于确定人体具有异常状态的系统和方法 | |
KR20200130087A (ko) | 핵산 정제 장치 및 핵산 정제 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21877612 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022555500 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021877612 Country of ref document: EP Effective date: 20230508 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180080274.4 Country of ref document: CN |